Genedrive (GDR) is “pleased to announce our FY25 final results, which show strong commercial and operational progress… look forward to our group continuing to grow and lead in emergency care pharmacogenetic testing”. What then about a current 1p share price comparing to more than double that in early 2025?
Describing itself as a “point of care molecular diagnostics company”, Genedrive (GDR) has announced “an amazing opportunity… to demonstrate the effectiveness of a new diagnostic approach”. What of this and the shares currently responding approaching 9% higher to 18.75p, a £18.6 million market cap?
With a hat tip to reader T I want you to consider the following sequence relating to Genedrive (GDR) and its very clear implication.
You can just smell it. All the signs are there and the company has stated that it will be placing before its year-end which is now just over three months away. At 40.75p, the market cap is £36.7 million and if you can short Genedrive (GDR) you should. So here’s why.
David Budd the, CEO of Genedrive plc (GDR) has been out ramping this week with an RNS that one of its devices has received a preliminarily recommendation for use in the NHS. Not only that but he’s been posting over on the LSE asylum to groom the posters over there:
When David Budd joined Genedrive (GDR) as its CEO in early 2016 the shares were 116p. Today after diabolical full year numbers the shares are now just 10.5p. So we are all in it together right? Er wrong. While investors have lost 91% of their cash Budd has trousered just over £2 million including an inexplicable 2020 bonus of more than £207,044 taking his total package that year to £444,615. Oink. Oink. It gets worse…
